Drug Trial Radar · NCT01524341
Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
Last checked: Nov 19, 2026Latest source record: May 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Jan 2012
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 1, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day
Conditions
- Malaria
Interventions
KAE609Drug
KAE609 was supplied as capsules for oral use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parasite clearance timeTime frame: From baseline to the time point when the blood parasite count is zero(up to a maximum of 5 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Tak, Thailand
Novartis Investigative Site
Tak Province, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.